Certara, Inc. (NASDAQ:CERT) Shares Sold by Nicolet Advisory Services LLC

Nicolet Advisory Services LLC lessened its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 39.8% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,956 shares of the company’s stock after selling 9,875 shares during the quarter. Nicolet Advisory Services LLC’s holdings in Certara were worth $159,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Blue Trust Inc. lifted its holdings in Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after buying an additional 822 shares in the last quarter. O Shaughnessy Asset Management LLC grew its stake in shares of Certara by 20.5% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 12,943 shares of the company’s stock worth $138,000 after acquiring an additional 2,202 shares in the last quarter. Venturi Wealth Management LLC increased its position in shares of Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after acquiring an additional 2,509 shares during the period. KBC Group NV raised its stake in shares of Certara by 64.1% in the fourth quarter. KBC Group NV now owns 7,998 shares of the company’s stock valued at $85,000 after acquiring an additional 3,125 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd boosted its holdings in Certara by 204.7% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock valued at $58,000 after purchasing an additional 3,656 shares during the period. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Trading Down 2.4 %

Shares of Certara stock opened at $9.55 on Friday. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a fifty day simple moving average of $12.14 and a 200-day simple moving average of $11.41. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -47.75, a PEG ratio of 9.29 and a beta of 1.64. Certara, Inc. has a 12-month low of $9.21 and a 12-month high of $19.18.

Analysts Set New Price Targets

Several brokerages have weighed in on CERT. TD Cowen assumed coverage on Certara in a report on Thursday, February 27th. They set a “buy” rating and a $16.00 price target on the stock. Barclays raised their target price on shares of Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. William Blair reiterated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Finally, Stephens restated an “overweight” rating and issued a $17.00 price objective on shares of Certara in a report on Thursday, February 27th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Certara has a consensus rating of “Moderate Buy” and a consensus price target of $15.83.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.